McAdam LLC Purchases 536 Shares of Johnson & Johnson (NYSE:JNJ)

McAdam LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,157 shares of the company’s stock after acquiring an additional 536 shares during the period. McAdam LLC’s holdings in Johnson & Johnson were worth $1,180,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC raised its position in shares of Johnson & Johnson by 20,130.0% during the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after buying an additional 3,437,397 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after buying an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after purchasing an additional 1,729,281 shares in the last quarter. Holocene Advisors LP purchased a new position in shares of Johnson & Johnson in the third quarter valued at $225,040,000. Finally, FMR LLC grew its holdings in shares of Johnson & Johnson by 7.4% in the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after purchasing an additional 1,265,748 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Guggenheim raised their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Stock Up 0.8 %

Shares of JNJ opened at $154.68 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a fifty day moving average price of $147.51 and a 200-day moving average price of $156.09. The firm has a market capitalization of $372.41 billion, a P/E ratio of 23.26, a P/E/G ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.21%. Johnson & Johnson’s payout ratio is currently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.